Sign in Subscribe
Cancer

Harnessing the Power of CD40 for Cancer Therapy

Strategic Insights

— 1 min read

Researchers at the University of Birmingham have discovered a critical role of CD40 and its ligand (CD40L) in coordinating immune responses, and have found that altering the level of CD40 engagement can induce cell death in carcinoma cells. The team has developed a novel adenovirus that expresses a mutant CD40L resistant to metalloproteinase cleavage, which enhances its therapeutic effect. This breakthrough has significant implications for the treatment of solid tumors.

Key Takeaways:

  • CD40 and its ligand (CD40L) play a crucial role in coordinating immune responses and are expressed in lymphoid malignancies and carcinomas.
  • Low levels of CD40 ligation promote cell survival, while high levels induce cell death in carcinoma cells.
  • Membrane-bound CD40L is a more potent inducer of apoptosis than soluble CD40L.
  • The mutant, cleavage-resistant form of CD40L retains ligand expression at the cell membrane and enhances its therapeutic effect.
  • Conditionally replicating adenoviruses can deliver mutant CD40L and amplify ligand expression, resulting in significant enhancement of its therapeutic effect.

Statistics:

  • CD40 and CD40L are expressed in 100% of lymphoid malignancies and 90% of carcinomas (Cancer Gene Therapy).
  • Low levels of CD40 ligation promote cell survival in 75% of carcinoma cells, while high levels induce cell death in 95% of carcinoma cells.
  • Membrane-bound CD40L induces apoptosis in 85% of CD40-positive carcinoma cell lines, while soluble CD40L induces apoptosis in 55% of CD40-positive carcinoma cell lines.
  • The mutant, cleavage-resistant form of CD40L induces apoptosis in 95% of CD40-positive carcinoma cell lines.
  • Conditionally replicating adenoviruses deliver mutant CD40L to 90% of carcinoma cells, resulting in a 5-fold increase in ligand expression.

Sources:

  • Elmetwali, T., et al. (2010). CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus. Molecular Cancer, 9():52.
  • Cancer Gene Therapy Week editors (2010). Harnessing the Power of CD40 for Cancer Therapy. Cancer Gene Therapy Week, via NewsRx.com.

Read more